Bigbear Pharmaceutical·Medication Guide

• U.S. FDA Approves Rinvoq (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn

  NORTH CHICAGO, Ill., May 18, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Ri···【Read More】

  Update: 2026-02-26Source: Haiou HealthViews: 72

• Rinvoq (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)

  NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved Rinvo···【Read More】

  Update: 2026-02-26Source: Haiou HealthViews: 72

• FDA Approves Updated Indication Statement for Rinvoq (upadacitinib) for the Treatment of Inflammator

  Previously, Rinvoq was indicated for adults with moderately to severely active UC or CD who had an inadequate response or intolerance to one or more t···【Read More】

  Update: 2026-02-26Source: Haiou HealthViews: 73

• Advanced Drugs Should Be Used First In Crohn's Disease, New Guidelines Suggest

  THURSDAY, Nov. 20, 2025 — New guidelines recommend doctors tackle Crohn’s disease head-on, calling for the use of cutting-edge drugs as early as possi···【Read More】

  Update: 2026-02-26Source: Haiou HealthViews: 79

• Can You Take Sotorasib with Food? A Complete Guide to Administration

  The usual recommended dose of sotorasib is 960 mg (8 tablets x 120 mg) once daily, taken on an empty stomach at least 1 hour before or 2 hours after e···【Read More】

  Update: 2026-02-25Source: Haiou HealthViews: 73

• Where to Buy Sotorasib Online Safely: Verified Pharmacies and Import Regulations

  Sotorasib is a targeted therapy for KRAS G12C-mutant non-small cell lung cancer (NSCLC). Its price varies significantly depending on region, dosage, p···【Read More】

  Update: 2026-02-25Source: Haiou HealthViews: 74

• Sotorasib Patient Assistance Program: How to Apply for Free or Reduced-Cost Lumakras

  Sotorasib (generic name: Sotorasib) is a prescription drug targeting a specific gene mutation (KRAS G12C) in non-small cell lung cancer. Its price is ···【Read More】

  Update: 2026-02-25Source: Haiou HealthViews: 73

• How Much Does Sotorasib Cost Per Month? Out-of-Pocket Expenses and Financial Assistance Programs

  The price of Sotorasib varies significantly depending on the region, purchase channel, and dosage. The specific price should be confirmed with the hos···【Read More】

  Update: 2026-02-25Source: Haiou HealthViews: 73

• Can Encorafenib Be Purchased in China? Availability and Purchase Channels

  Encorafenib is indicated for patients with BRAF-V600E or V600K mutation-positive unresectable or metastatic melanoma, as well as BRAF-V600E mutation-p···【Read More】

  Update: 2026-02-25Source: Haiou HealthViews: 72

• What is the Latest Price of Encorafenib (Braftovi) per Box in 2026

  Encorafenib is a targeted therapy used for cancers with BRAF gene mutations. Information regarding its price, clinical efficacy, and preparation for m···【Read More】

  Update: 2026-02-25Source: Haiou HealthViews: 73

• FDA Approves Braftovi + Mektovi Combination

  Approval Details and BackgroundArray BioPharma Announces FDA Approval of Braftovi (encorafenib) in Combination with Mektovi (binimetinib) for Unresect···【Read More】

  Update: 2026-02-25Source: Haiou HealthViews: 72

• FDA Approves Braftovi (encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mut

  Approval Details and BackgroundApril 8, 2020 - Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved B···【Read More】

  Update: 2026-02-25Source: Haiou HealthViews: 73

• FDA Approves Braftovi (encorafenib) with Mektovi (binimetinib) for Metastatic Non-Small Cell Lung Ca

  Approval Details and BackgroundNEW YORK--(BUSINESS WIRE) October 12, 2023 -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Admin···【Read More】

  Update: 2026-02-25Source: Haiou HealthViews: 72

• U.S. FDA Approves Pfizer’s Braftovi Combination Regimen as First-Line Treatment of BRAF V600E-Mutant

  Approval Details and BackgroundNEW YORK--(BUSINESS WIRE) December 20, 2024 -- Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Admi···【Read More】

  Update: 2026-02-25Source: Haiou HealthViews: 73

• ASCO: Encorafenib + Cetuximab + Chemo Lengthens Survival in Metastatic CRC

  Study Publication and BackgroundFRIDAY, May 30, 2025 -- For patients with BRAF V600E-mutated metastatic colorectal cancer, progression-free and overal···【Read More】

  Update: 2026-02-25Source: Haiou HealthViews: 73